Clinical trials: Vehicle
Acne Vulgaris
Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
Therapeutic equivalence and safety study
- Trial name
- NCT02929719
- Testing
- Test., Aczone Gel 5%
- Volunteers
- 1,134 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To demonstrate the superiority of the investigational medicinal product (IMP; 0.3% OPA-15406 ointment, 1% OPA-15406 ointment, or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in…
- Trial name
- NCT03911401
- Testing
- 0.3% OPA-15406, 1% OPA-15406
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Progressive Keratoconus
Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
To evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking (CXL) in impeding the progression of, and/or reducing corneal curvature (Kmax) in eyes with progressive keratoconus.
- Trial name
- NCT03442751
- Testing
- Test Article A, Test Article B, KXL medical device system
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Glaukos Corporation
Acne Vulgaris
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
The primary objective of this study is to compare the safety and efficacy of once daily application of IDP-123 Lotion to Tazorac Cream, 0.1%, Vehicle Lotion, and Vehicle Cream in subjects with moderate to severe acne vulgaris.
- Trial name
- NCT02525822
- Testing
- IDP-123 Lotion, Tazorac Cream, 0.1%,, Vehicle Cream
- Volunteers
- 210 people
- Sponsor
- Valeant Pharmaceuticals
Atopic Dermatitis
Study of 0417 Ointment in the Treatment of Atopic Dermatitis
The aim of this trial is to assess the efficacy of 0417 Ointment in the Treatment of Atopic Dermatitis. Treatment medication will be administered as follows: Apply a thin layer of ointment to affected skin areas twice daily and…
- Trial name
- NCT01139450
- Testing
- 0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%
- Where
- United States
- Volunteers
- 899 people
- Sponsor
- Fougera Pharmaceuticals Inc.
All Acutely Ill or Injured Patients Receiving Care by Ambulance Personnel
Videoconferencing Between Ambulances and Physician Manned Rapid Response Vehicles, Effects on On-site Patient Treatment and Patterns of Referral
Physician manned rapid response vehicles are a limited resource in the prehospital handling of acute patients. In this study mobile videoconferencing between ambulances and the rapid response vehicles enables patient consultation…
- Trial name
- NCT02093975
- Testing
- iPad air with 4G/3G SIM card
- Where
- 2 sites in Denmark
- Sponsor
- University of Aarhus
Hyperhidrosis
Study of Glycopyrronium in Axillary Hyperhydrosis
The study is a randomized, double-blind, vehicle controlled, parallel group study, designed to assess the efficacy and safety of glycopyrronium topical wipes, once daily, compared to vehicle in subjects with axillary…
- Trial name
- NCT02530281
- Testing
- glycopyrronium Topical Wipes, Vehicle
- Where
- 31 sites in United States, Germany
- Volunteers
- 344 people
- Sponsor
- Journey Medical Corporation
Allergic Conjunctivitis
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis:
- Trial name
- NCT05579730
- Testing
- Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035%
- Where
- 4 sites in United States
- Volunteers
- 188 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01881113
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aciex Therapeutics, Inc.
Acne Vulgaris
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.
- Trial name
- NCT02815280
- Testing
- FMX-101, 4% minocycline foam, Vehicle Foam
- Where
- 36 sites in United States, Dominican Republic
- Volunteers
- 495 people
- Sponsor
- Vyne Therapeutics Inc.
Obesity, Water; Lack of
Preventing Early Childhood Obesity, Part 1: Long-term Follow-up
This study extends follow up on of Native American (NA) mothers and their children (now age 3-5 years) enrolled in the 1:1 randomized controlled trial of the Family Spirit Nurture (FSN) intervention designed to prevent early…
- Conditions
- Obesity, Water; Lack of, Childhood Obesity, Feeding Behavior
- Trial name
- PECO1-LTF (NCT05424471)
- Testing
- Family Spirit Nurture (FSN), Control Group - Vehicle Safety
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Plaque Psoriasis
Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study
This study is a multi-center, randomized, double-blind, vehicle-controlled phase III study to evaluate the efficacy, safety, and PK profile of roflumilast cream 0.3% in Chinese subjects ≥6 years of age with plaque psoriasis.
- Trial name
- NCT06648772
- Testing
- Roflumilast Cream 0.3%, Vehicle cream
- Where
- 31 sites in China
- Volunteers
- 190 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Driving Behavior
Washington State Driving Intervention Research Study
The goal of this clinical trial is to test the effect of hazard perception and attention maintenance training and testing on driving performance.
- Trial name
- NCT06146634
- Testing
- Hazard Perception Training, Vehicle Maintenance Training, Attention Maintenance Training
- Where
- United States
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Healthy
Kinematics of Youth (Age 12-15) on Stationary All Terrain Vehicles
To assess the relationship between pre-teen/teen height, age, weight, gender, and body proportions and shape and size of youth and comfort and safety when operating adult All Terrain Vehicles (ATV).
- Trial name
- ATV (NCT00692029)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Kentucky
Acne Vulgaris
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
The objective of this study is to compare the relative efficacy and safety of the test formulation Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) to the marketed formulation Duac® Topical Gel…
- Trial name
- NCT01769664
- Testing
- Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel, Duac® Topical Gel
- Volunteers
- 650 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
This is an Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study. The main objective is to evaluate bioequivalence of Test formulation (Clindamycin Phosphate 1.2%/Benzoyl…
- Trial name
- NCT02005666
- Testing
- Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel
- Where
- 36 sites in United States, India
- Volunteers
- 850 people
- Sponsor
- Zydus Lifesciences Limited
Tinea Pedis
Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis
To demonstrate comparable safety and efficacy of Taro Pharmaceuticals Inc. butenafine hydrochloride cream 1% (test product) and Lotrimin Ultra® cream (reference listed drug) in the treatment of interdigital tinea pedis, and to…
- Trial name
- NCT00835510
- Testing
- Butenafine cream 1% manufactured by Taro, Lotrimin Ultra (butenafine) 1%, Butenafine Vehicle manufactured by Taro
- Where
- 17 sites in United States, Belize
- Volunteers
- 548 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Pulp Necrosis, Irreversible Pulpitis
CLINICAL AND RADIOGRAPHIC SUCCESS OF MODIFIED LSTR TECHNIQUES IN PRIMARY SECOND MOLARS
This study aimed to evaluate and compare the clinical and radiographic success of different antibiotic and vehicle modifications of the Lesion Sterilization and Tissue Repair (LSTR) technique in infected mandibular primary second…
- Trial name
- NCT07836686
- Testing
- 3Mix-MP Antibiotic Paste, 3Mix-NS Antibiotic Paste, 2Mix-MP Antibiotic Paste
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Uşak University
Pediculus Humanus Capitis, Head Lice
A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation
The main purpose of this study is to investigate the safety and efficacy of an investigational treatment for head lice infestation against a placebo.
- Trial name
- NCT00528021
- Testing
- BGC20-0582
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Boston Scientific Corporation
MILD TO SEVERE ACNE VULGARIS
Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and Placebo
ZIANA® (clindamycin phosphate 1.2% and tretinoin 0.025%) gel, marketed by Medicis, The Dermatology Company®, is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01257906
- Testing
- CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL, ZIANA®, Vehicle Control
- Where
- India
- Volunteers
- 1,225 people
- Sponsor
- Actavis Mid-Atlantic LLC